{"analyses":[{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"99","ciUpperLimit":"0.91","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0012","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"8.34","value":"6.80"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"7.03","value":"4.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","dispersionType":"99% Confidence Interval","groups":[{"description":"Participants received 40 mg cabozantinib oral tablets once daily + 1200 mg IV infusion of atezolizumab once every 3 weeks for up to 38 months.","id":"OG000","title":"Experimental Arm: Cabozantinib + Atezolizumab"},{"description":"Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.","id":"OG001","title":"Control Arm: Sorafenib"}],"paramType":"MEDIAN","populationDescription":"PITT population included the first 372 participants randomized to the experimental (cabozantinib + atezolizumab) arm and control (sorafenib) arm.","reportingStatus":"POSTED","timeFrame":"From the date of first participant randomization up to 28 months","title":"Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population","type":"PRIMARY","unitOfMeasure":"months"}